 SALT LAKE CITY, Dec. 11, 2020 GLOBE NEWSWIRE -- In a spotlight poster discussion at the 2020 San Antonio Breast Cancer Symposium SABCS, Myriad Genetics NASDAQ: MYGN, a global leader in molecular diagnostics and precision medicine, today presented a new study that shows how its myRisk Hereditary Cancer and riskScore tests can better inform individualized clinical screening and prevention strategies for women at risk of developing breast cancer. The new Myriad study highlights how riskScore, a proprietary tool used to evaluate a womans risk of developing breast cancer, can accurately provide breast cancer risk information into a personalized assessment model for women carrying a pathogenic variant PV in the ATM gene. 